Anergis discovers and develops proprietary, pharmaceutical-grade COP allergy vaccines for ultra-fast Allergy Immunotherapy based on its unique technology of Contiguous Overlapping Peptides (COP).

COP allergy vaccines can spare allergy patients three years of conventional subcutaneous or sublingual desensitization treatment.

AllerT, the most advanced COP allergy vaccine of Anergis, has demonstrated excellent safety and immunogenicity. Moreover, vaccinated patients developed a long-term immune memory against the natural birch pollen allergen and were shown to experience less allergy symptoms than patients who received a placebo, during natural conditions of pollen exposure. (AllerT results)



  • Biopôle Building SC-A
    Route de la Corniche 4
    CH-1066 Epalinges
  • Email:

This website uses cookies to ensure you get the best experience on our website.